Page 121 - Read Online

Page 12 of 13 Best et al. Hepatoma Res 2020;6:62 I http://dx.doi.org/10.20517/2394-5079.2020.56

Gastroenterology 2004;127:S108-12.
43. Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small
hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999;30:125-30.
44. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in
small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001.
45. Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-
proven hepatocellular carcinoma. Int J Biol Markers 2001;16:105-11.
46. Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon
General Hospital, Myanmar. Acta Med Okayama 2002;56:317-20.
47. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular
carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-21.
48. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of
biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79-87.
49. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005;19:91-9.
50. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-
fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci 2011;102:1025-31.
51. Choi JY, Jung SW, Kim HY, Kim M, Kim Y, et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to
total-AFP. World J Gastroenterol 2013;19:339-46.
52. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development
of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-9.
53. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, et al. Incidence of hepatocellular carcinoma and associated risk factors in
hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
54. Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, et al. The detection of hepatocellular carcinoma using a prospectively developed and
validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23:144-53.
55. Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, et al. Performance of serum alpha-fetoprotein levels in the diagnosis of hepatocellular
carcinoma in patients with a hepatic mass. HPB (Oxford) 2014;16:366-72.
56. Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of
hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875-86.e6.
57. Best J, Bilgi H, Heider D, Schotten C, Manka P, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly
improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol 2016;54:1296-305.
58. Best J, Bechmann LP, Sowa JP, Sydor S, Dechene A, et al. GALAD score detects early hepatocellular carcinoma in an international
cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-35.e4.
59. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate,
and lung cancer. Clin Cancer Res 2001;7:4060-6.
60. Zhao J, Dong L, Lu B, Wu G, Xu D, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma
via induction of apoptosis. Gastroenterology 2008;135:956-68.
61. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J
Gastroenterol 2006;101:2051-9.
62. Wan HG, Xu H, Gu YM, Wang H, Xu W, et al. Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res
Hepatol Gastroenterol 2014;38:706-14.
63. Li J, Chen X, Dai M, Huang S, Chen J, et al. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: a
meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53.
64. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008;7:2787-90.
65. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular
carcinoma. Gastroenterology 2003;125:89-97.
66. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt
signaling. Cancer Res 2005;65:6245-54.
67. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma,
is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
68. Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic
review with meta-analysis. Arch Med Res 2014;45:580-8.
69. Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing
hepatocellular carcinoma. Hepatogastroenterology 2011;58:1718-24.
70. Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, et al. GALAD score for hepatocellular carcinoma detection in comparison to liver
ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2019;28:531-8.
71. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in
USA: risk and prognosis prediction. Mol Carcinog 2013;52 Suppl 1:E139-47.
72. Tang S, Zhang J, Mei TT, Guo HQ, Wei XH, et al. Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular
carcinoma: a meta-analysis. BMC Cancer 2019;19:1128.
73. Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. miRNA signature in NAFLD: a turning point for a non-invasive